Novel thiazole derivatives: a patent review (2008 – 2012. Part 2)

Bibliography

• Leoni AL, Locatelli A, Morigi R, Rambaldi M. Novel thiazole derivatives: a patent review (2008-2012; Part 1). Expert Opin Ther Pat 2014;24(2):201-16
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Moriello AS. 2-Amino-4-arylthiazole compounds as TRPA1 antagonists (WO 2012085662): a patent evaluation. Expert Opin Ther Pat 2013.23:119-47
   Google Scholar
• Hoyer D. Serotonin (5-HT) receptors: pharmacology, function and structure. Acta Pharm Sinic 2013;34:43-4
   Google Scholar
• Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high-affinity for tricyclic psychotropic-drugs. Mol Pharmacol 1993;43:320-7
   PubMed Web of Science ®Google Scholar
• Kohen R, Metcalf MA, Khan N, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996;66:47-56
   PubMed Web of Science ®Google Scholar
• Shinkai T, Ohmori O, Kojima H, et al. Association study of the 5-HT6 receptor gene in schizophrenia. Am J Med Genet 1999;88:120-2
   PubMed Web of Science ®Google Scholar
• Woolley ML, Bentley JC, Sleight AJ, et al. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001;41:210-19
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Fisas A, et al. Selective 5-HT(6) receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;117:207-31
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Ivanenkov YA. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin Ther Pat 2012;22:917-64
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Ivanenkov YA, Skorenko AV. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Expert Opin Ther Pat 2012;22:1123-68
   PubMed Web of Science ®Google Scholar
• Chu C, Lister A, Nordvall G, et al. Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor. WO126939; 2006
   Google Scholar
• Esteve Labor. Sulphonamide derivatives, the preparation thereof and the application of same as medicaments. WO042175; 2003
   Google Scholar
• Merce-Vidal R, Xavier Codony S, Dordal-Zueras A. Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments. EP1676841; 2006
   Google Scholar
• Fisas A, Codony X, Romero G, et al. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006;148:973-83
   PubMed Web of Science ®Google Scholar
• Esteve Labor. Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands. WO135927; 2009
   Google Scholar
• Mas Prio J, Torrens Jover A. Substituted N-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands. US0105555; 2011
   Google Scholar
• Hogenauer EK. Latest advances in the cannabinoids. Expert Opin Ther Pat 2007;17:1457-76
   Web of Science ®Google Scholar
• Thakur GA, Tichkule R, Bajaj S, et al. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 2009;19:1647-73
   PubMed Web of Science ®Google Scholar
• Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009-present. Expert Opin Ther Pat 2012;22:495-510
   PubMed Web of Science ®Google Scholar
• Abbott Lab. Novel compounds as cannabinoid receptor ligands. WO09114566; 2009
   Google Scholar
• Abbott Lab. USA Imine derivatives as cannabinoid receptor ligands. WO10019547; 2009
   Google Scholar
• Abbott Lab. USA Novel compounds as cannabinoid receptor ligands. WO10033543; 2010
   Google Scholar
• Abbott Lab. USA. Novel compounds as cannabinoid receptor ligands. WO10054024; 2010
   Google Scholar
• Abbott Lab. USA. Novel compounds as cannabinoid receptor ligands. WO10028338; 2010
   Google Scholar
• Abbott Lab. USA. Prodrug compounds useful as cannabinoid receptor ligands. WO11075522; 2010
   Google Scholar
• Abbott Lab. USA. Process for preparing cannabinoid receptors ligands. WO11075525; 2011
   Google Scholar
• Micheli F, Heidbreder C. Dopamine D3 receptor antagonists: a patent review (2007-2012). Expert Opin Ther Pat 2013;23:363-81
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Giros B, Martres MP, et al. Molecular-cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-51
   PubMed Web of Science ®Google Scholar
• Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 2005;48:3663-79
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals. D2 Receptor Ligand. US0215841A1; 2009
   Google Scholar
• Motac Neuroscience Ltd. Medicaments. US0046153; 2011
   Google Scholar
• Wang S, Chen J, Collins G, et al. Selective ligands for the dopamine 3 (D3) receptor and methods of using the same. US8283368B2; 2012
   Google Scholar
• Otani K, Ujike H, Tanaka Y, et al. The GABA type A receptor alpha 5 subunit gene is associated with bipolar I disorder. Neurosci Lett 2005;381:108-13
   PubMedGoogle Scholar
• McCauley JL, Olson LM, Delahanty R, et al. A linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit cluster and association to autism. Am J Med Genet B 2004;131B:51-9
   PubMed Web of Science ®Google Scholar
• Solis-Anez E, Delgado-Luengo W, Hernandez ML. Autism, chromosome 15 and the GAbaergic dysfunction hypothesis. Invest clin 2007;48:529-41
   PubMedGoogle Scholar
• Cui Y, Costa RM, Murphy GG, et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008;135:549-60
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche, Inc. Thiazoles. US0286116A1; 2010
   Google Scholar
• Broad LM, Sher E, Astles PC, et al. Selective alpha 7 nicotinic acetylcholine receptor ligands for the treatment of neuropsychiatric diseases. Drugs Fut 2007;32:161-70
   Google Scholar
• Couturier S, Bertrand D, Matter JM, et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 1990;5:847-56
   PubMed Web of Science ®Google Scholar
• Alkondon M, Albuquerque EX. The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex. In: Descarries L, Krnjevic K, Steriade M, editors. Acetylcholine in the cerebral cortex. Elsevier B.V, Amsterdam, Netherlands; 2004. 145 p. 109-20
   Google Scholar
• Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 2004;25:317-24
   PubMed Web of Science ®Google Scholar
• Gundisch D. Nicotinic acetylcholine receptor ligands as potential therapeutics. Expert Opin Ther Pat 2005;15:1221-39
   Web of Science ®Google Scholar
• Romanelli MN, Gualtieri F. The quest for the treatment of cognitive impairment: alpha(7) nicotinic and alpha(5) GABA(A) receptor modulators. Expert Opin Ther Pat 2007;17:1365-77
   Web of Science ®Google Scholar
• D’Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer’s disease pyramidal neurons. Curr Pharm Des 2006;12:677-84
   PubMed Web of Science ®Google Scholar
• Gotti C, Riganti L, Vailanti S, et al. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des 2006;12:407-28
   PubMed Web of Science ®Google Scholar
• Vincler M, McIntosh JM. Targeting the alpha(9)alpha(10) nicotinic acetylcholine receptor to treat severe pain. Exp Opin Ther Targets 2007;11:891-7
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Santos MD, Alkondon M, et al. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Adv Biosci 2001;15:S19-25
   Google Scholar
• Hevers W, Luddens H. The diversity of GABA(A) receptors - Pharmacological and electrophysiological properties of GABA(A) channel subtypes. Mol Neurobiol 1998;18:35-86
   PubMedGoogle Scholar
• Abbott Lab. Thiazolylidine urea and amide derivatives and methods of use thereof. US016347; 2009
   Google Scholar
• Nakanishi S, Nakajima Y, Masu M, et al. Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev 1998;26:230-5
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Hopkins CR. Metabotropic glutamate receptor 4 (mGlu(4))-positive allosteric modulators for the treatment of Parkinson’s disease: historical perspective and review of the patent literature. Expert Opin Ther Pat 2012;22:461-81
   PubMed Web of Science ®Google Scholar
• Addex Pharmaceuticals S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO010455; 2009
   Google Scholar
• Addex Pharmaceuticals S.A. Heterotricyclic compounds as positive allosteric modulators of metabotropic glutamate receptors. WO079238; 2010
   Google Scholar
• Addex Pharmaceuticals S.A. Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO079239; 2010
   Google Scholar
• Campo B. Novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators for the treatment of Parkinson’s disease and anxiety. Curr Neuropharm 2011;9:abstract 22
   Google Scholar
• Celanire S, Bolea C, Brueckner S, et al. Discovery and characterization of novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators. Curr Neuropharm 2011;9:8-9
   PubMedGoogle Scholar
• Addex Pharmaceuticals S.A. Novel pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO010222; 2011
   Google Scholar
• Addex Pharmaceuticals S.A. Preparation of 4-amino-thiazoles and 3-amino-1,2,4-thiadiazoles and their use as allosteric modulators of metabotropic glutamate receptors. WO086163; 2011
   Google Scholar
• Addex Pharmaceuticals S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors. WO009009; 2012
   Google Scholar
• Addex Pharmaceuticals S.A. and Merck Sharp & Dohme Corp. Novel tetrahydropyrazolo[3,4-b]azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors. WO009001; 2012
   Google Scholar
• Addex Pharmaceuticals S.A. and Merck Sharp & Dohme Corp. Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors. WO009000; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. and Addex Pharma S.A. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors. WO006760; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. and Addex Pharmaceuticals S.A. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors. WO008999; 2012
   Google Scholar
• Bolea C. Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO079239; 2010
   Google Scholar
• Janssen Pharmaceutica. Bicyclic thiazoles as allosteric modulators of mglur5 receptors. US0252800; 2012
   Google Scholar
• Norton GR, Woodiwiss AJ, McGinn RJ, et al. Adenosine A(1) receptor-mediated antiadrenergic effects are modulated by A(2a) receptor activation in rat heart. Am J Physiol 1999;276:H341-9
   PubMedGoogle Scholar
• Auchampach JA, Bolli R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol 1999;276:H1113-16
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-64
   PubMed Web of Science ®Google Scholar
• Imai E, Fujii M, Kohno Y, et al. Adenosine A1 receptor antagonist improves intradialytic hypotension. Kidney Int 2006;69:877-83
   PubMedGoogle Scholar
• Palobiofarma SL. New compounds as adenosine a1 receptor antagonists. US0311703; 2010
   Google Scholar
• Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2(A), but not A(1), receptors mediate the arousal effect of caffeine. Nat Neurosci 2005;8:858-9
   PubMed Web of Science ®Google Scholar
• Varani K, Gessi S, Dalpiaz A, et al. Pharmacological and biochemical characterization of purified A(2a) adenosine receptors in human platelet membranes by H-3 -CGS 21680 binding. Br J Pharmacol 1996;117:1693-701
   PubMedGoogle Scholar
• Uesaka N, Sawada T. Therapeutic agent for motor disorders. WO126082; 2010
   Google Scholar
• Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and selective ligands for histamine receptors-H-3. Nature 1987;327:117-23
   PubMed Web of Science ®Google Scholar
• Leurs R, Blandina P, Tedford C, et al. Therapeutic potential histamine H-3 receptor agonists and antagonists. Trends Pharmacol Sci 1998;19:177-83
   PubMed Web of Science ®Google Scholar
• Black L, Cowart M, et al. Benzothiazole and benzoxazole derivatives and methods of use. WO085945; 2009
   Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51
   PubMed Web of Science ®Google Scholar
• Aissaoui H, Boss C, Gude M, et al. Thiazolidine derivatives as orexin receptor antagonists. WO11724; 2008
   Google Scholar
• Lewis C, Neidhart S, Holy C, et al. Coexpression of P2X(2) and P2X(3) receptor subunits can account for ATP-gated currents in sensory neurons. Nature 1995;377:432-5
   PubMed Web of Science ®Google Scholar
• Zhong Y, Dunn PM, Xiang ZH, et al. Pharmacological and molecular characterization of P2X receptors in rat pelvic ganglion neurons. Br J Pharmacol 1998;125:771-81
   PubMedGoogle Scholar
• Yiangou Y, Facer P, Baecker PA, et al. ATP-gated ion channel P2X(3) is increased in human inflammatory bowel disease. Neurogastroenterol Motil 2001;13:365-9
   PubMed Web of Science ®Google Scholar
• Wynn G, Ma B, Ruan HZ, et al. Purinergic component of mechanosensory transduction is increased in a rat model of colitis. Am J Physiol 2004;287:G647-57
   PubMed Web of Science ®Google Scholar
• Roche R&D Center China Ltd. Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists. US0132494; 2008
   Google Scholar
• Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists. WO122504; 2010
   Google Scholar
• Okamoto H, Takuwa N, Gonda K, et al. EDG1 is a functional sphingosine-l-phosphate receptor that is linked via a G(i/o) to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem 1998;273:27104-10
   PubMed Web of Science ®Google Scholar
• Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913-22
   PubMed Web of Science ®Google Scholar
• Pyne S, Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 2000;88:115-31
   PubMed Web of Science ®Google Scholar
• Takuwa Y, Okamoto Y, Yoshioka K, et al. Sphingosine-1-phosphate signaling in physiology and diseases. Biofactors 2012;38:329-37
   PubMed Web of Science ®Google Scholar
• Chun J, Goetzl EJ, Hla T, et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002;54:265-9
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005;5:560-70
   PubMed Web of Science ®Google Scholar
• Webb M, Tharn CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004;153:108-21
   PubMed Web of Science ®Google Scholar
• Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004;20:16-24
   PubMed Web of Science ®Google Scholar
• Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-44
   PubMed Web of Science ®Google Scholar
• Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. Faseb J 2004;18:551-3
   PubMed Web of Science ®Google Scholar
• Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005;6:1228-35
   PubMed Web of Science ®Google Scholar
• Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005;108:308-19
   PubMed Web of Science ®Google Scholar
• Hale JJ, Doherty G, Toth L, et al. Selecting against S1P(3) enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists. Bioorg Med Chem Lett 2004;14:3501-5
   PubMedGoogle Scholar
• Glaxo Group Ltd. Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (S1P1) receptor agonists. WO145202; 2010
   Google Scholar
• Wagner C, Hansch GM, Stegmaier S, et al. The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 2001;31:1173-80
   PubMed Web of Science ®Google Scholar
• Radu CG, Liao H. Deoxycytidine kinase binding compounds. WO122368; 2012
   Google Scholar
• Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G-protein-coupled signal-transduction pathways in human-disease. J Clin Invest 1993;92:1119-25
   PubMedGoogle Scholar
• Nathans J, Merbs SL, Sung CH, et al. Molecular-genetics of human visual pigments. Annu Rev Genet 1992;26:403-24
   PubMedGoogle Scholar
• Holtzman EJ, Kolakowski LF, Obrien D, et al. A null mutation in the vasopressin-V2 receptor gene (AVPR2) associated with nephrogenic diabetes-insipidus in the hopewell kindred. Hum Mol Genet 1993;2:1201-4
   PubMedGoogle Scholar
• Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11:90-4
   PubMed Web of Science ®Google Scholar
• Katsuma S, Hatae N, Yano T, et al. Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1. J Biol Chem 2005;280:19507-15
   PubMed Web of Science ®Google Scholar
• MacDonald PE, El-kholy W, Riedel MJ, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51:S434-42
   PubMed Web of Science ®Google Scholar
• Janssen P, Rotondo A, Mule F, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharm Ther 2013;37:18-36
   PubMed Web of Science ®Google Scholar
• Epple R, Azimioara M, et al. Compounds and methods for modulating G protein-coupled receptors. WO103501; 2008
   Google Scholar
• He X, Zhu X, Yang K, et al. Compounds and methods for modulating G protein-coupled receptors. WO008831; 2010
   Google Scholar
• Menendez-Gutierrez MP, Roszer T, Ricote M. Biology and Therapeutic Applications of Peroxisome Proliferator-Activated Receptors. Curr Top Med Chem 2012;12:548-84
   PubMed Web of Science ®Google Scholar
• Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat 2012;22:803-41
   PubMed Web of Science ®Google Scholar
• Nippon Chemiphar Co. Activating agent for peroxisome proliferator activated receptor delta. US20090298896A1; 2009
   Google Scholar
• Anti-doping agency warns athletes of black market drug. New Sci 2013;31(4):169
   Google Scholar
• Cerenis Therapeutics S.A. & Nippon Chemiphar Co. Ltd. Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases. US20110092517A1; 2011
   Google Scholar
• Cerenis Therapeutics S.A. Novel uses of ppar delta agonists. WO154023; 2008
   Google Scholar
• Sri International. PPAR-delta ligands and methods of their use. US20090163481A1; 2009
   Google Scholar
• Shionogi & Co., Ltd, Institute Of Medicinal Molecular Design, Inc. Derivative having ppar agonistic activity. US20090286974A1; 2009
   Google Scholar
• Noy N. Methods of treating metabolic disorders. US0137671A1; 2009
   Google Scholar
• Seoul Nat Univ Ind Foundation. Thiazole Compound (as PPARδ) ligand and pharmaceutical, cosmetic and health food comprised thereof. US0041723A1; 2010
   Google Scholar
• Sanofi Aventis Deutschland. Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists. US7709509B2; 2010
   Google Scholar
• Genomics Institute Of The Novartis Research Foundation. Compounds and compositions as PPAR modulators. US0192203A1; 2009
   Google Scholar
• Schapira AHV, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013;12:747-55
   PubMed Web of Science ®Google Scholar
• Yao BB, Hsieh G, Daza AV, et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 2,2,3,3-tetramethyl-cyclopropanecarboxylic acid 3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene-amide, using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 2009;328:141-51
   PubMed Web of Science ®Google Scholar